| Revenues |
Note 3. Revenues Revenues are recognized under guidance within ASC 606, Revenue from Contracts with Customers. The following table presents our disaggregated revenue for the periods presented (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2024 | | 2023 | | 2024 | | 2023 | | JAKAFI revenues, net | $ | 705,973 | | | $ | 682,384 | | | $ | 1,277,812 | | | $ | 1,262,353 | | | OPZELURA revenues, net | 121,695 | | | 80,233 | | | 207,419 | | | 136,785 | | | ICLUSIG revenues, net | 26,862 | | | 29,087 | | | 57,205 | | | 56,772 | | | PEMAZYRE revenues, net | 20,269 | | | 21,572 | | | 37,945 | | | 44,047 | | | MINJUVI/MONJUVI revenues, net | 31,116 | | | 13,159 | | | 54,990 | | | 19,715 | | | ZYNYZ revenues, net | 651 | | | 570 | | | 1,118 | | | 570 | | | Total product revenues, net | 906,566 | | | 827,005 | | | 1,636,489 | | | 1,520,242 | | | JAKAVI product royalty revenues | 99,317 | | | 90,448 | | | 188,912 | | | 167,140 | | | OLUMIANT product royalty revenues | 31,702 | | | 32,009 | | | 62,291 | | | 66,164 | | | TABRECTA product royalty revenues | 5,298 | | | 4,799 | | | 10,532 | | | 8,976 | | | PEMAZYRE product royalty revenues | 876 | | | 349 | | | 1,424 | | | 761 | | | Total product royalty revenues | 137,193 | | | 127,605 | | | 263,159 | | | 243,041 | | | Milestone and contract revenues | — | | | — | | | 25,000 | | | — | | | Total revenues | $ | 1,043,759 | | | $ | 954,610 | | | $ | 1,924,648 | | | $ | 1,763,283 | |
For further information on the MINJUVI/MONJUVI revenues, refer to Note 6, and for further information on our revenue-generating contracts, refer to Note 8.
|